Is SpringWorks Therapeutics Stock a Good Investment?
SpringWorks Therapeutics Investment Advice | SWTX |
- Examine SpringWorks Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research SpringWorks Therapeutics' leadership team and their track record. Good management can help SpringWorks Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact SpringWorks Therapeutics' business and its evolving consumer preferences.
- Compare SpringWorks Therapeutics' performance and market position to its competitors. Analyze how SpringWorks Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if SpringWorks Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about SpringWorks Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in SpringWorks Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if SpringWorks Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine SpringWorks Therapeutics Stock
Researching SpringWorks Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.89. SpringWorks Therapeutics had not issued any dividends in recent years.
To determine if SpringWorks Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding SpringWorks Therapeutics' research are outlined below:
| SpringWorks Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 5.45 M. Net Loss for the year was (325.1 M) with profit before overhead, payroll, taxes, and interest of 35 M. | |
| SpringWorks Therapeutics currently holds about 334.54 M in cash with (222.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.81. | |
| SpringWorks Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Evercore ISI sets Outperform rating on Spring Works shares, cites potential |
SpringWorks Therapeutics Quarterly Good Will |
|
SpringWorks Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in SpringWorks Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to SpringWorks Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact SpringWorks Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises SpringWorks Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-04 | 2021-09-30 | -0.76 | -0.84 | -0.08 | 10 | ||
2021-05-05 | 2021-03-31 | -0.51 | -0.62 | -0.11 | 21 | ||
2020-08-12 | 2020-06-30 | -0.36 | -0.47 | -0.11 | 30 | ||
2024-02-27 | 2023-12-31 | -1.24 | -1.45 | -0.21 | 16 | ||
2022-08-04 | 2022-06-30 | -1.2 | -1.41 | -0.21 | 17 | ||
2022-05-05 | 2022-03-31 | -1.02 | -1.26 | -0.24 | 23 | ||
2022-02-24 | 2021-12-31 | -0.88 | -1.15 | -0.27 | 30 | ||
2021-08-04 | 2021-06-30 | -0.67 | -0.97 | -0.3 | 44 |
Know SpringWorks Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as SpringWorks Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading SpringWorks Therapeutics backward and forwards among themselves. SpringWorks Therapeutics' institutional investor refers to the entity that pools money to purchase SpringWorks Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 1.6 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.6 M | Geode Capital Management, Llc | 2024-06-30 | 1.6 M | Woodline Partners Lp | 2024-06-30 | 1.4 M | Artal Group S A | 2024-06-30 | 1.3 M | Fiera Capital Corporation | 2024-06-30 | 1.3 M | Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 1.2 M | Duquesne Family Office Llc | 2024-06-30 | 1 M | Polar Capital Holdings Plc | 2024-06-30 | 1000 K | Fmr Inc | 2024-09-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 6.7 M |
SpringWorks Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.7 B.Market Cap |
|
SpringWorks Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.48) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.52) | (0.49) |
Determining SpringWorks Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if SpringWorks Therapeutics is a good buy. For example, gross profit margin measures SpringWorks Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of SpringWorks Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in SpringWorks Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SpringWorks Therapeutics. Check SpringWorks Therapeutics' Beneish M Score to see the likelihood of SpringWorks Therapeutics' management manipulating its earnings.
Evaluate SpringWorks Therapeutics' management efficiency
SpringWorks Therapeutics has return on total asset (ROA) of (0.3428) % which means that it has lost $0.3428 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5933) %, meaning that it created substantial loss on money invested by shareholders. SpringWorks Therapeutics' management efficiency ratios could be used to measure how well SpringWorks Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. At this time, SpringWorks Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 13.3 M in 2024, whereas Other Assets are likely to drop slightly above 2.2 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.92 | 5.54 | |
| Tangible Book Value Per Share | 9.74 | 5.53 | |
| Enterprise Value Over EBITDA | (6.25) | (6.57) | |
| Price Book Value Ratio | 3.68 | 3.86 | |
| Enterprise Value Multiple | (6.25) | (6.57) | |
| Price Fair Value | 3.68 | 3.86 | |
| Enterprise Value | 1.2 B | 1.3 B |
Understanding the operational decisions made by SpringWorks Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.792 |
Basic technical analysis of SpringWorks Stock
As of the 22nd of November, SpringWorks Therapeutics has the Risk Adjusted Performance of (0.02), coefficient of variation of (3,092), and Variance of 7.81. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of SpringWorks Therapeutics, as well as the relationship between them.SpringWorks Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SpringWorks Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SpringWorks Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases SpringWorks Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
SpringWorks Therapeutics' Outstanding Corporate Bonds
SpringWorks Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. SpringWorks Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most SpringWorks bonds can be classified according to their maturity, which is the date when SpringWorks Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAG58 | View | |
| SPR 9375 30 NOV 29 Corp BondUS85205TAN00 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAK60 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| SPRINT P 7625 Corp BondUS85207UAK16 | View | |
| Sprint 7625 percent Corp BondUS85207UAJ43 | View | |
| SPRINT NEXTEL P Corp BondUS85208NAE04 | View |
Understand SpringWorks Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing SpringWorks Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 2.1 | |||
| Coefficient Of Variation | (3,092) | |||
| Standard Deviation | 2.8 | |||
| Variance | 7.81 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.46) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 11.04 | |||
| Value At Risk | (4.36) | |||
| Potential Upside | 4.46 | |||
| Skewness | 0.4172 | |||
| Kurtosis | 1.59 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 2.1 | |||
| Coefficient Of Variation | (3,092) | |||
| Standard Deviation | 2.8 | |||
| Variance | 7.81 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.46) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 11.04 | |||
| Value At Risk | (4.36) | |||
| Potential Upside | 4.46 | |||
| Skewness | 0.4172 | |||
| Kurtosis | 1.59 |
Consider SpringWorks Therapeutics' intraday indicators
SpringWorks Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of SpringWorks Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 120227.0 | |||
| Daily Balance Of Power | 0.8071 | |||
| Rate Of Daily Change | 1.07 | |||
| Day Median Price | 37.92 | |||
| Day Typical Price | 38.29 | |||
| Price Action Indicator | 2.46 | |||
| Period Momentum Indicator | 2.72 |
SpringWorks Therapeutics Corporate Filings
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 25th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
SpringWorks Stock media impact
Far too much social signal, news, headlines, and media speculation about SpringWorks Therapeutics that are available to investors today. That information is available publicly through SpringWorks media outlets and privately through word of mouth or via SpringWorks internal channels. However, regardless of the origin, that massive amount of SpringWorks data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of SpringWorks Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of SpringWorks Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to SpringWorks Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive SpringWorks Therapeutics alpha.
SpringWorks Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards SpringWorks Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
SpringWorks Therapeutics Corporate Management
| Badreddin Edris | Chief Officer | Profile | |
| Mary Smith | Chief Officer | Profile | |
| Kim Diamond | Vice Relations | Profile | |
| James MD | Chief Officer | Profile | |
| Michael Nofi | Chief Officer | Profile | |
| TaiAn Lin | Chief Officer | Profile | |
| Saqib JD | CEO Director | Profile |
Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.